Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, RPT1G, for cancers. RPT1G is designed to target ...

ConferenceHeidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 26.03.2025 / 09:23 CET/CESTThe issuer is solely responsible for the content of this ...

Neutropenia in individuals with a congenital defect or patients with cancer who are undergoing chemotherapy is generally treated with granulocyte colony-stimulating factor (G-CSF) to restore ...